Clinical aspects of palliative care in advanced Parkinson's disease

BMC Palliative Care

Volumn 11, Issue , 2012, Pages

  Lokk, Johan ^a   Delbari, Ahmad ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SABZEVAR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical aspects; End stage; Palliative care; Parkinson's disease

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CLOZAPINE; LEVODOPA; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOLCAPONE;

AKINESIA; APATHY; AUTONOMIC DYSFUNCTION; BLADDER DYSFUNCTION; COGNITIVE DEFECT; CONSTIPATION; DECUBITUS; DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG ABSORPTION; DRUG HALF LIFE; DYSKINESIA; DYSPHAGIA; DYSTONIA; FREEZING; HALLUCINATION; HUMAN; HYPOKINESIA; ORTHOSTATIC HYPOTENSION; PAIN; PALLIATIVE THERAPY; PARKINSON DISEASE; PSYCHOSIS; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; SLEEP DISORDER; SUBSTANTIA NIGRA;

EID: 84867740271     PISSN: None     EISSN: 1472684X     Source Type: Journal    
DOI: 10.1186/1472-684X-11-20     Document Type: Review

References (62)

1. Epidemiologic approaches to the study of Parkinson's disease etiology. Checkoway H, Nelson L, Epidemiology 1999 10 3 327 336 10.1097/00001648- 199905000-00023 10230846 (Pubitemid 29187771)
2. Palliative care in Parkinson's disease: implications for neuroscience nursing. Bunting-Perry L, J Neurosci Nurs 2006 38 2 106 113 10.1097/01376517- 200604000-00006 16681291
3. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. De Rijk M, Breteler M, Graveland G, Ott A, Grobbee D, Van der Meché F, Hofman A, Neurology 1995 45 12 2143 2146 10.1212/WNL.45.12.2143 8848182 (Pubitemid 27100237)
4. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Bower J, Maraganore D, McDonnell S, Rocca W, Neurology 1999 52 6 1214 1220 10.1212/WNL.52.6.1214 10214746 (Pubitemid 29177924)
5. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees A, Neurology 2008 71 7 474 480 10.1212/01.wnl.0000310812.43352. 66 18579806
6. Parkinson's disease, palliative care and older people: Part 2. Thomas S, Macmahon D, Nurs Older People 2004 16 2 22 26 15552500
7. A palliative care approach to end-stage neurodegenerative conditions. Low J, Pang W, Chan D, Chye R, Ann Acad Med Singapore 2003 32 6 778 784 14716946 (Pubitemid 38197338)
8. Palliative Care-The World Health Organization's Global Perspective. Sepúlveda C, Marlin A, Yoshida T, Ullrich A, J Pain Symptom Manage 2002 24 2 91 96 10.1016/S0885-3924(02)00440-2 12231124 (Pubitemid 35291983)
9. Palliative Care in Amyotrophic Lateral Sclerosis, Parkinson's Disease, and Multiple Sclerosis. Elman L, Houghton D, Wu G, Hurtig H, Markowitz C, McCluskey L, J Palliat Med 2007 10 2 433 457 10.1089/jpm.2006.9978 17472516 (Pubitemid 46740218)
10. Extending palliative care to patients with Parkinson's disease. Wilcox S, Br J Hosp Med (Lond) 2010 71 1 26 30
11. Managing the late complications of Parkinson's disease. Waters C, Neurology 1997 49 1 Supplement 1 49 S57 9222274 (Pubitemid 27304771)
12. Continuous levodopa for advanced Parkinson's disease. Lundqvist C, Neuropsychiatr Dis Treat 2007 3 3 335 348 19300565 (Pubitemid 47215009)
13. Protein intake and treatment of Parkinson's disease with levodopa. Mena I, Cotzias G, N Engl J Med 1975 23 4 181 184
14. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Baruzzi A, Contin M, Riva R, Procaccianti G, Albani F, Tonello C, Zoni E, Martinelli P, Clin Neuropharmacol 1987 10 6 527 537 10.1097/00002826-198712000-00004 3427559 (Pubitemid 17167170)
15. Protein redistribution diet restores motor function in patients with dopa-resistant «off» periods. Pincus J, Barry K, Neurology 1988 38 3 481 483 10.1212/WNL.38.3.481 3126411 (Pubitemid 18083693)
16. Management of motor complications in advanced Parkinson's disease. Melamed E, Ziv I, Djaldetti R, Mov Disord 2007 22 S17 379 S384 10.1002/mds.21680 18175400 (Pubitemid 350134192)
17. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Kurth M, Tetrad J, Irwin I, Lyness W, Langston J, Neurology 1993 43 5 1036 1039 10.1212/WNL.43.5.1036 8492922 (Pubitemid 23150583)
18. Impact of the motor complications of Parkinson's disease on the quality of life. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F, Mov Disord 2005 20 2 224 230 10.1002/mds.20279 15384126 (Pubitemid 40361128)
19. Quality of life and Parkinson's disease. Koplas P, Gans H, Wisely M, Kuchibhatla M, Cutson T, Gold D, Taylor CT, Schenkman M, J Gerontol A Biol Sci Med Sci 1999 54 4 197 M202 10.1093/gerona/54.4.M197 10219011
20. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Widnell K, Comella C, Mov Disord 2005 20 S11 30 S37 10.1002/mds.20461 15822107 (Pubitemid 40846909)
21. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Durif F, Devaux I, Pere J, Delumeau J, Bourdeix I, Eur Neurol 2000 45 2 111 118 (Pubitemid 32215799)
22. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Olanow C, Koller W, Neurology 1998 50 3 Suppl 3 1 S57 9633678
23. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Brannan T, Yahr M, Ann Neurol 1995 37 1 95 98 10.1002/ana.410370117 7818264
24. Comparison of motor fluctuations and l-dopa-induced dyskinesias in patients with familial and sporadic Parkinson's disease. Papapetropoulos S, Argyriou A, Ellul J, Chroni E, Eur J Neurol 2004 11 2 115 119 10.1046/j.1351-5101.2003.00727.x 14748772 (Pubitemid 38230787)
25. Motor fluctuations and dyskinesia in Parkinson's disease. Nutt J, Parkinsonism Relat Disord 2001 8 2 101 108 10.1016/S1353-8020(01)00024-4 11489675 (Pubitemid 32728023)
26. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Ahlskog J, Muenter M, Mov Disord 2001 16 3 448 458 10.1002/mds.1090 11391738 (Pubitemid 36041148)
27. Dystonia and parkinsonism. Jankovic J, Tintner R, Parkinsonism Relat Disord 2001 8 2 109 121 10.1016/S1353-8020(01)00025-6 11489676 (Pubitemid 32728024)
28. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment. Olanow C, Watts R, Koller W, Neurology 2001 56 Supplement 5 1 S88 10.1212/WNL.56.suppl-5.S1 11402154 (Pubitemid 32532291)
29. Treatment of advanced Parkinsons disease. Diamond A, Jankovic J, Expert Rev Neurother 2006 6 8 1181 1197 10.1586/14737175.6.8.1181 16893346 (Pubitemid 44231976)
30. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Aarsland D, Andersen K, Larsen J, Lolk A, Kragh-Sorensen P, Arch Neurol 2003 60 3 387 392 10.1001/archneur.60.3.387 12633150 (Pubitemid 36314364)
31. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. Hely M, Morris J, Reid W, O'Sullivan D, Williamson P, Rail D, Broe GA, Margrie S, J Neurol Neurosurg Psychiatr 1994 57 8 903 910 10.1136/jnnp.57.8.903 8057111 (Pubitemid 24251051)
32. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, et al. Mov Disord 2006 21 7 916 923 10.1002/mds.20844 16547944 (Pubitemid 44184590)
33. Longitudinal outcome of Parkinson's disease patients with psychosis. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R, Parkinson Study Group, Neurology 2003 60 11 1756 1761 10.1212/01.WNL.0000068010.82167.CF 12796526 (Pubitemid 36737069)
34. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Friedman J, Factor S, Mov Disord 2000 15 2 201 211 10.1002/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D 10752567 (Pubitemid 30167909)
35. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner W, Neurology 2006 66 7 968 975 10.1212/01.wnl.0000215437.80053.d0 16606907 (Pubitemid 44044778)
36. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Burn DJ, Mov Disord 2002 17 3 445 454 10.1002/mds.10114 12112190 (Pubitemid 36040955)
37. Depression in Parkinson's disease: clinical correlates and outcome. Rojo A, Aguilar M, Garolera M, Cubo E, Navas I, Quintana S, Parkinsonism Relat Disord 2003 10 1 23 28 10.1016/S1353-8020(03)00067-1 14499203 (Pubitemid 37117388)
38. What contributes to quality of life in patients with Parkinson's disease? Schrag A, Jahanshahi M, Quinn N, J Neurol Neurosurg Psychiatr 2000 69 3 308 312 10.1136/jnnp.69.3.308 10945804 (Pubitemid 30636233)
39. Psychiatric complications in Parkinson disease. Weintraub D, Stern M, Am J Geriatr Psychiatr 2005 13 10 844 851 (Pubitemid 46638672)
40. A systematic review of prevalence studies of dementia in Parkinson's disease. Aarsland D, Zaccai J, Brayne C, Mov Disord 2005 20 10 1255 1263 10.1002/mds.20527 16041803 (Pubitemid 41645899)
41. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Rolinski M, Fox C, Maidment I, McShane R, Cochrane Database Syst Rev 2012 14 3 D006504
42. The nighttime problems of Parkinson's disease. Lees A, Blackburn N, Campbell V, Clin Neuropharmacol 1988 11 6 512 519 10.1097/00002826-198812000- 00004 3233589 (Pubitemid 19006460)
43. Range of neuropsychiatric disturbances in patients with Parkinson's disease. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings JL, J Neurol Neurosurg Psychiatry 1999 67 4 492 496 10.1136/jnnp.67.4.492 10486397 (Pubitemid 29438205)
44. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. Starkstein S, Mayberg H, Preziosi T, Andrezejewski P, Leiguarda R, Robinson R, J Neuropsychiatry Clin Neurosci 1992 4 2 134 139 1627973
45. Apathy in Parkinson's disease. Pluck G, Brown R, J Neurol Neurosurg Psychiatr 2002 73 6 636 642 10.1136/jnnp.73.6.636 12438462 (Pubitemid 35448846)
46. Characterization of swallowing and defecation in Parkinson's disease. Edwards L, Quigley E, Harned R, Hofman R, Pfeiffer R, Am J Gastroenterol 1994 89 1 15 25 8273792 (Pubitemid 24020046)
47. Nonmotor complications in Parkinson's disease. Adler C, Mov Disord 2005 20 S11 23 S29 10.1002/mds.20460 15822106 (Pubitemid 40846908)
48. Treatment of dysautonomia associated with Parkinson's disease. Mostile G, Jankovic J, Parkinsonism Relat Disord 2009 15 Suppl 3 224 S232 20082997
49. Colonic transit time and rectoanal videomanometry in Parkinson's disease. Sakakibara R, Odaka T, Uchiyama T, Asahina M, Yamaguchi K, Yamaguchi T, Yamanishi T, Hattori T, J Neurol Neurosurg Psychiatr 2003 74 2 268 272 10.1136/jnnp.74.2.268 12531969 (Pubitemid 36160697)
50. Frequency of bowel movements and the future risk of Parkinson's disease. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW, Neurology 2001 57 3 456 462 10.1212/WNL.57.3.456 11502913 (Pubitemid 32757593)
51. The management of constipation in palliative care: clinical practice recommendations. Larkin PJ, Sykes NP, Centeno C, Ellershaw JE, Elsner F, Eugene B, Gootjes JR, Nabal M, Noguera A, Ripamonti C, et al. Palliat Med 2008 22 7 796 807 10.1177/0269216308096908 18838491
52. Camptocormia: pathogenesis, classification, and response to therapy. Azher S, Jankovic J, Neurology 2005 65 3 355 359 10.1212/01.wnl.0000171857. 09079.9f 16087897 (Pubitemid 41099795)
53. Speech and swallowing disorders in Parkinson disease. Sapir S, Ramig L, Fox C, Curr Opin Otolaryngol Head Neck Surg 2008 16 3 205 210 10.1097/MOO.0b013e3282febd3a 18475072 (Pubitemid 351677652)
54. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. Kenney C, Jankovic J, Expert Opin Pharmacother 2007 8 9 1329 1335 10.1517/14656566.8.9.1329 17563266 (Pubitemid 47034418)
55. Pressure Ulcers in Individuals Receiving Palliative Care: A National Pressure Ulcer Advisory Panel White Paper (C). Langemo D, Black J, Adv Skin Wound Care 2010 23 2 59 72 10.1097/01.ASW.0000363502.84737.c8 20087072
56. Living with a pressure ulcer: a descriptive study of patients' experiences. Fox C, Br J Community Nurs 2002 7 6 Suppl 10 22 12066077
57. Caregiver strain in Parkinson's disease and the impact of disease duration. Lökk J, Eur J Phys Rehabil Med 2008 44 1 39 45 18385627
58. Health-related quality of life evaluation by proxy in Parkinson's disease: Approach using PDQ-8 and EuroQoL-5D. Martínez-Martín P, Benito-León J, Alonso F, Catalán M, Pondal M, Zamarbide I, Mov Disord 2004 19 3 312 318 10.1002/mds.10656 15022186 (Pubitemid 38961086)
59. Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M, Parkinsonism Relat Disord 2006 12 1 35 41 10.1016/j. parkreldis.2005.06.011 16271496 (Pubitemid 43037151)
60. Parkinson's disease, palliative care and older people: Part 1. Thomas S, Macmahon D, Nurs Older People 2004 16 1 22 26 15552500
61. Palliative care in neurology. Foley K, Carver A, Neurol Clin 2001 19 4 789 799 10.1016/S0733-8619(05)70047-5 11854100 (Pubitemid 33051852)
62. Hospice and nonhospice nursing home residents. Parker-Oliver D, Porock D, Zweig S, Rantz M, Petroski G, J Palliat Med 2003 6 1 69 75 Feb 10.1089/10966210360510136 12710577 (Pubitemid 36159785)